Health and Fitness Health and Fitness
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ] - Market Wire
Naturea?s Sunshine Products Announces Board Change
[ Fri, Oct 15th 2010 ] - Market Wire
Celgene completa la adquisicin de Abraxis
[ Fri, Oct 15th 2010 ] - Market Wire
Celgene Conclui Aquisio da Abraxis
[ Fri, Oct 15th 2010 ] - Market Wire
Celgene completa l'acquisizione di Abraxis
[ Fri, Oct 15th 2010 ] - Market Wire
Celgene schliet bernahme von Abraxis ab
[ Fri, Oct 15th 2010 ] - Market Wire
Celgene finalise la?acquisition da?Abraxis
[ Fri, Oct 15th 2010 ] - Market Wire
Celgene Completes Acquisition of Abraxis
[ Fri, Oct 15th 2010 ] - Market Wire
New Data Evaluating Laquinimod for the Treatment .. ple Sclerosis Demonstrate Neuroprotective Effects
[ Fri, Oct 15th 2010 ] - Market Wire
ALGN, FCN, GOOG, SWY, GCI
[ Fri, Oct 15th 2010 ] - Market Wire
se podran ahorrar US$ 3.5 billones durante 25 aos .. dicare y del modelo de arancel por servicio de Me
[ Fri, Oct 15th 2010 ] - Market Wire
Phase II Study with Ocrelizumab Shows Significant .. Disease Activity for Multiple Sclerosis Patients
[ Fri, Oct 15th 2010 ] - Market Wire
Bioniche Scientists Present at Modern Vaccine &; Adjuvant Formulation Conference in France
[ Fri, Oct 15th 2010 ] - Market Wire
Aetna Signs New Agreement with the Washington Hospital
[ Fri, Oct 15th 2010 ] - Market Wire
Allos Therapeutics' Pralatrexate Granted Orphan M .. for the Treatment of Hodgkin Lymphoma by the Euro
[ Fri, Oct 15th 2010 ] - Market Wire
ZIOPHARM Oncology to Present at BioCenturya?s Newsmakers in the Biotech Industry Conference
[ Fri, Oct 15th 2010 ] - Market Wire
Orthofix International Announces Date For Release of Third Quarter Results
[ Fri, Oct 15th 2010 ] - Market Wire
Medtronic Clinical Trial Receives FDA Approval to .. CoreValve® System for Aortic Valve Implantation
[ Fri, Oct 15th 2010 ] - Market Wire
NPS Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
[ Fri, Oct 15th 2010 ] - Market Wire
Inhibitex Completes Enrollment in Phase II Clinical Trial of FV-100 in Shingles Patients
[ Fri, Oct 15th 2010 ] - Market Wire
Ariad to Present at the 17th Annual NewsMakers in the Biotech Industry Conference
[ Fri, Oct 15th 2010 ] - Market Wire
Exelixis Announces Webcast of Presentation at the .. wsMakers in the Biotechnology Industry Conference
Thu, October 14, 2010
[ Thu, Oct 14th 2010 ] - Market Wire
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
[ Thu, Oct 14th 2010 ] - Market Wire
Essilor to Acquire 50% of Shamir Optical
[ Thu, Oct 14th 2010 ] - Market Wire
SurModics Announces Organizational Changes to Red .. Cost Structure and Renew Focus on Business Units
[ Thu, Oct 14th 2010 ] - Market Wire
Naturea?s Sunshine Products Reports Change in Executive Officers
[ Thu, Oct 14th 2010 ] - Market Wire
MEDNAX 2010 Third Quarter Conference Call/Webcast Scheduled for November 2, 2010
[ Thu, Oct 14th 2010 ] - Market Wire
Helicos BioSciences Corporation Announces Appointment of Ivan Trifunovich as President and CEO
[ Thu, Oct 14th 2010 ] - Market Wire
Enzo Biochem Reports Fourth Quarter and Year End Results
[ Thu, Oct 14th 2010 ] - Market Wire
Knopp Neurosciences forma nueva empresa matriz para ampliar sus operaciones y misin
[ Thu, Oct 14th 2010 ] - Market Wire
Knopp Neurosciences richt nieuwe moedermaatschappij op voor uitbreiding activiteiten en missie

Knopp Neurosciences richt nieuwe moedermaatschappij op voor uitbreiding activiteiten en missie


Published on 2010-10-14 11:30:49 - Market Wire
  Print publication without navigation


PITTSBURGH--([ BUSINESS WIRE ])--Knopp Neurosciences Inc. ("KNS") meldt de oprichting van een moedermaatschappij genaamd Knopp Biosciences LLC met het oog op de ontwikkeling naar een breder gentegreerd biofarmaceutisch bedrijf. De bedrijfsherstructurering volgt een overeenkomst van augustus j.l, waaronder Biogen Idec (NASDAQ: BIIB) exclusieve wereldwijde rechten verwerft voor de ontwikkeling en vermarkting van KNS-760704 (dexpramipexole). KNS blijft de licensieverlener voor onderdelen in verband met KNS-760704 maar heeft zijn andere activa en activiteiten aan Knopp Biosciences uitbesteed inclusief een overeenkomstige aandeelhouderherkapitalisatie. De overgedragen activa en bedrijvigheden betreffen o.a. de onderzoeksactiviteiten van KNS op het gebied van van mitochondriale ziektemechanismen.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

Contributing Sources